Hezen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 02-07-2024
- Paid Up Capital ₹ 0.50 M
as on 02-07-2024
- Company Age 20 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.10 Cr
as on 02-07-2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth -0.63%
(FY 2023)
- Total Assets %
(FY 2023)
About Hezen Pharmaceuticals
The Corporate was formerly known as Hezen Pharmaceuticals Private Limited. The Company is engaged in the Infrastructure And Utilities Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹10.10 Cr.
Raghuveer Acharya, Venkat Kudimuskula, and Prasad Kudimuskula serve as directors at the Company.
- CIN/LLPIN
U24239TG2004PLC043758
- Company No.
043758
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
27 Jul 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Hezen Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghuveer Acharya  | Director | 25-May-2006 | Current |
| Venkat Kudimuskula | Director | 27-Jul-2004 | Current |
| Prasad Kudimuskula | Director | 27-Jul-2004 | Current |
Financial Performance of Hezen Pharmaceuticals.
Hezen Pharmaceuticals Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth dipped by a decrease of 0.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Hezen Pharmaceuticals?
In 2023, Hezen Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Octans Nutra Private LimitedActive 32 years 8 monthsVenkat Kudimuskula and Prasad Kudimuskula are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of Hyderabad Creation Date: 02 Jan 2006 | ₹6.50 Cr | Open |
Syndicate Bank Creation Date: 12 Aug 2005 | ₹1.00 M | Open |
Syndicate Bank Creation Date: 01 Jul 2005 | ₹3.50 Cr | Open |
How Many Employees Work at Hezen Pharmaceuticals?
Unlock and access historical data on people associated with Hezen Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hezen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hezen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
